{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T16:40:11Z","timestamp":1707756011581},"reference-count":98,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:title>Lije\u010denje Osteoporoze<\/jats:title><jats:p>Osteoporoza je jedna od naj\u010de\u0161\u0107ih metaboli\u010dkih bolesti i zahva\u0107a 8 % do 10 % stanovni\u0161tva. Budu\u0107i da je prijelom najte\u017ea posljedica osteoporoze, vrlo je va\u017eno otkriti bolesnike koji imaju rizik nastanka prijeloma, dati im farmakolo\u0161ku terapiju i savjetovati im promjenu na\u010dina \u017eivota. Nekoliko je lijekova pokazalo sposobnost smanjenja broja prijeloma kralje\u017enice i\/ili perifernog skeleta u bolesnika s osteoporozom. Antiresorptivni su lijekovi temelj terapije, ali su i anaboli\u010dki lijekovi odnedavno pro\u0161irili mogu\u0107nosti lije\u010denja. Antiresorptivni lijekovi, estrogeni, selektivni modulatori estrogenskih receptora, bisfosfonati i kalcitonin, djeluju tako da smanjuju ko\u0161tanu pregradnju. Paratireoidni hormon poti\u010de novo stvaranje kosti popravljaju\u0107i arhitekturu i gusto\u0107u kosti. Stroncijev ranelat smanjuje rizik osteoporoti\u010dnih prijeloma djeluju\u0107i na oboje - smanjenje razgradnje i pove\u0107anje izgradnje kosti. Druga potencijalna lije\u010denja osteoporoze tako\u0111er su opisana u ovome \u010dlanku.<\/jats:p>","DOI":"10.2478\/v10004-007-0009-3","type":"journal-article","created":{"date-parts":[[2007,4,2]],"date-time":"2007-04-02T16:38:54Z","timestamp":1175531934000},"page":"55-71","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Osteoporosis"],"prefix":"10.2478","volume":"58","author":[{"given":"Petra","family":"\u0160imi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zlatko","family":"Giljevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velimir","family":"\u0160imuni\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodan","family":"Vuki\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Kor\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1185\/030079905X50598","article-title":"Prevalence of vitamin D inadequacy in a minimal trauma fracture population","volume":"21","author":"C Simonelli","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1621100","article-title":"Increased osteoclast development after estrogen lossmediation by interleukin-6","volume":"257","author":"R Jilka","year":"1992","journal-title":"Science"},{"key":"3","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1172\/JCI119333","article-title":"Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency","volume":"99","author":"P Ammann","year":"1997","journal-title":"J Clin Invest"},{"key":"4","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1073\/pnas.88.15.6613","article-title":"Avian osteoclasts as estrogen target cells","volume":"88","author":"M Oursler","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"5","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.273.5279.1171","article-title":"Drugs' link to genes reveals estrogen's many sides","volume":"273","author":"E Pennisi","year":"1996","journal-title":"Science"},{"key":"6","first-page":"21","article-title":"Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions","volume":"8","author":"M Tzukerman","year":"1994","journal-title":"Mol Endocrinol"},{"key":"7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"J Manson","year":"2003","journal-title":"New Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1359\/jbmr.060119","article-title":"Effect of the women's health initiative on osteoporosis therapy and expenditure in Medicaid","volume":"21","author":"J Udell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"S Hulley","year":"1998","journal-title":"JAMA"},{"key":"10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.288.7.872","article-title":"Postmenopausal hormone replacement therapy: scientific review","volume":"288","author":"H Nelson","year":"2002","journal-title":"JAMA"},{"key":"11","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa030311","article-title":"Effects of estrogen plus progestin on health-related quality of life","volume":"348","author":"J Hays","year":"2003","journal-title":"New Engl J Med"},{"key":"12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1172\/JCI116985","article-title":"Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats","volume":"93","author":"L Black","year":"1994","journal-title":"J Clin Invest"},{"key":"13","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"P Delmas","year":"1997","journal-title":"New Engl J Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.berh.2005.06.007","article-title":"Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?","volume":"19","author":"P Sambrook","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1126\/science.273.5279.1222","article-title":"Identification of an estrogen response element activated by metabolites of 17\u03b2-estradiol raloxifene","volume":"273","author":"N Yang","year":"1996","journal-title":"Science"},{"key":"16","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.270.5240.1354","article-title":"Sequence and characterization of a coactivator for the steroid hormone receptor superfamily","volume":"270","author":"S Onate","year":"1995","journal-title":"Science"},{"key":"17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"E Barrett-Connor","year":"2006","journal-title":"New Engl J Med"},{"key":"18","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1517\/14656566.7.16.2301","article-title":"Raloxifene and the prevention of breast cancer","volume":"7","author":"T Bevers","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"19","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene: results from a 3-year randomized clinical trial","volume":"281","author":"B Ettinger","year":"1999","journal-title":"JAMA"},{"key":"20","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"CORE Investigators. (CORE Investigators): Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"S Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"21","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"T Storm","year":"1990","journal-title":"New Engl J Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/mol.56.1.131","article-title":"Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs","volume":"56","author":"H Benford","year":"1999","journal-title":"Mol Pharmacol"},{"key":"23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/mol.61.5.1255","article-title":"Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP\/ATP translocase by a nonhydrolyzable, adenine-containing metabolite","volume":"61","author":"P Lehenkari","year":"2002","journal-title":"Mol. Pharmacol"},{"key":"24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/abbi.1999.1502","article-title":"Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase","volume":"373","author":"J Bergstrom","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"S Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.0224","article-title":"Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase\/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo","volume":"255","author":"E van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/1566524023362104","article-title":"Bisphosphonate mechanism of action","volume":"2","author":"G Rodan","year":"2002","journal-title":"Curr Mol Med"},{"key":"28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/PL00004164","article-title":"Bisphosphonates: pharmacology, mechanisms of action and clinical uses","volume":"2","author":"R Russell","year":"1999","journal-title":"Osteoporos Int"},{"key":"29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X100276","article-title":"Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis","volume":"22","author":"J Iwamoto","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women","volume":"80","author":"R Recker","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"31","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"H Bone","year":"2004","journal-title":"New Engl J Med"},{"key":"32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group","volume":"338","author":"D Hosking","year":"1998","journal-title":"New Engl J Med"},{"key":"33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2796.2004.01317.x","article-title":"Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International","volume":"255","author":"P Sambrook","year":"2004","journal-title":"J Intern Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"16","author":"S Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","article-title":"STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis","volume":"355","author":"R de Nijs","year":"2006","journal-title":"New Engl J Med"},{"key":"36","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results form a multinational, double-blind, placebocontrolled trial","volume":"85","author":"I Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"J Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"38","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"S Harris","year":"1999","journal-title":"JAMA"},{"key":"39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"J Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-ranging study","volume":"19","author":"P Ravn","year":"1996","journal-title":"Bone"},{"key":"41","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"B Riis","year":"2001","journal-title":"J Bone Miner Res"},{"key":"42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"D Thiebaud","year":"1997","journal-title":"Am J Med"},{"key":"43","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"P Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0889-8529(02)00060-9","volume":"32","author":"S Silverman","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jcem-57-4-819","article-title":"The sensitivity of isolated osteoclasts to morphological transformation by calcitonin","volume":"57","author":"T Chambers","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"46","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.2174\/1381612033453622","article-title":"Calcitonin for osteoporosis and bone pain","volume":"9","author":"N Mehta","year":"2003","journal-title":"Curr Pharm Des"},{"key":"47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10067-006-0228-z","article-title":"The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain","volume":"26","author":"D Ofluoglu","year":"2007","journal-title":"Clin Rheumatol"},{"key":"48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"C Chesnut 3rd","year":"2000","journal-title":"Am J Med"},{"key":"49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S8756-3282(02)00714-7","article-title":"Analgesic effects of calcitonin","volume":"30","author":"G Lyritis","year":"2002","journal-title":"Bone"},{"key":"50","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1210\/endo.137.8.8754785","article-title":"Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function","volume":"137","author":"A Miyauchi","year":"1996","journal-title":"Endocrinology"},{"key":"51","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1001\/jama.285.11.1482","article-title":"Ipriflavone Multicenter European Fracture Study. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial","volume":"285","author":"P Alexandersen","year":"2001","journal-title":"JAMA"},{"key":"52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF02409438","article-title":"Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis","volume":"33","author":"A Darby","year":"1981","journal-title":"Calcif Tissue Int"},{"key":"53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0300-595X(72)80050-1","article-title":"Physiology and chemistry of parathyroid hormone","volume":"1","author":"J Parsons","year":"1972","journal-title":"Clin Endocrino Metab"},{"key":"54","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI113885","article-title":"Insulinlike growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures","volume":"8","author":"E Canalis","year":"1989","journal-title":"J Clin Invest"},{"key":"55","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"R Neer","year":"2001","journal-title":"New Engl J Med"},{"key":"56","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.1999.14.4.536","article-title":"Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits","volume":"14","author":"T Hirano","year":"1999","journal-title":"J Bone Miner Res"},{"key":"57","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"D Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"58","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/0026-0495(89)90232-1","article-title":"A proposed mechanism of the mitogenic action of fluoride on bone cells: inhibition of the activity of an osteoblastic acid phosphatase","volume":"38","author":"K Lau","year":"1989","journal-title":"Metabolism"},{"key":"59","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"J Finkelstein","year":"2003","journal-title":"New Engl J Med"},{"key":"60","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide after treatment with raloxifene or alendronate","volume":"19","author":"B Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"61","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","article-title":"Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women","volume":"13","author":"F Cosman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"62","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"PaTH Study Investigators The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"D Black","year":"2003","journal-title":"New Engl J Med"},{"key":"63","first-page":"7","article-title":"The bone growth-stimulating PTH and osteosarcoma","volume":"6","author":"J Whitfield","year":"2001","journal-title":"Medscape Womens Health"},{"key":"64","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.6623079","article-title":"Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells","volume":"222","author":"J Farley","year":"1983","journal-title":"Science"},{"key":"65","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1056\/NEJM199003223221203","article-title":"Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis","volume":"322","author":"B Riggs","year":"1990","journal-title":"New Engl J Med"},{"key":"66","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF01625446","article-title":"A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis","volume":"1","author":"M Kleerekoper","year":"1991","journal-title":"Osteoporosis Int"},{"key":"67","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"P Meunier","year":"2004","journal-title":"New Engl J Med."},{"key":"68","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/jbmr.5650110915","article-title":"Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration","volume":"11","author":"G Boivin","year":"1996","journal-title":"J Bone Miner Res"},{"key":"69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s002230010055","article-title":"Mechanisms of action and therapeutic potential of strontium in bone","volume":"69","author":"P Marie","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"70","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1053\/meta.2002.33360","article-title":"Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice","volume":"51","author":"P Delannoy","year":"2002","journal-title":"Metabolism"},{"key":"71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jbmr.5650080512","article-title":"An uncoupling agent containin strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats","volume":"9","author":"P Marie","year":"1993","journal-title":"J Bone Miner Res"},{"key":"72","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s00198-002-1347-2","article-title":"The mineralization of bone tissue: a forgotten dimension in osteoporosis research","volume":"3","author":"G Boivin","year":"2003","journal-title":"Osteoporosis Int"},{"key":"73","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study","volume":"90","author":"J Reginster","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"74","first-page":"206","article-title":"Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial","volume":"87","author":"P Meunier","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"75","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1359\/jbmr.1997.12.12.1971","article-title":"Cation sensing receptors in bone: A novel paradigm for regulation bone remodeling?","volume":"12","author":"L Quarles","year":"1997","journal-title":"J Bone Miner Res"},{"key":"76","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-642-77991-6_3","author":"R Baron","year":"1993","journal-title":"Handbook of Experimental Pharmacology"},{"key":"77","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/345442a0","article-title":"The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene","volume":"345","author":"H Yoshida","year":"1990","journal-title":"Nature"},{"key":"78","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/jbmr.5650050716","article-title":"Impairment of macrophage colonystimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op\/op mouse","volume":"5","author":"R Felix","year":"1990","journal-title":"J Bone Miner Res"},{"key":"79","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1084\/jem.173.1.269","article-title":"Congenital osteoclast deficiency in osteopetrotic op\/op mice is cured by injections of macrophage colony stimulating factor","volume":"173","author":"H Kodama","year":"1991","journal-title":"J Exp Med"},{"key":"80","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","article-title":"Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice","volume":"64","author":"P Soriano","year":"1991","journal-title":"Cell"},{"key":"81","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1172\/JCI116521","article-title":"a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption <i>in vitro<\/i> and hypercalcemia <i>in vivo.<\/i>","volume":"91","author":"T Yoneda","year":"1993","journal-title":"J Clin Invest"},{"key":"82","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1210\/endo.132.3.8440195","article-title":"Inhibition of osteoclastic bone resorption <i>in vivo<\/i> by echistatin an \"arginylglycyl-aspartyl\" (RDG) containing peptide","volume":"132","author":"J Fisher","year":"1993","journal-title":"Endocrinology"},{"key":"83","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1172\/JCI119404","article-title":"A peptidomimetic antagonist of the \u03b1<sub>v<\/sub> \u03b2<sub>3<\/sub> integrin inhibits bone resorption <i>in vitro<\/i> and prevents osteoporosis <i>in vivo.<\/i>","volume":"99","author":"V Engleman","year":"1997","journal-title":"J Clin Invest"},{"key":"84","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jbmr.5650040603","article-title":"Perspectives-adhesion receptors in bone. J","volume":"4","author":"M Horton","year":"1989","journal-title":"Bone Miner Res"},{"key":"85","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1083\/jcb.39.3.676","article-title":"The action of parathyroid hormone on the excretion and synthesis of lysosomal enzymes and on the extracellular release of acid by bone cells","volume":"39","author":"E Vaes","year":"1968","journal-title":"J Cell Biol"},{"key":"86","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1210\/endo-103-6-1969","article-title":"Comparison of the effects of stimulators and inhibitors of resorption on the release of lysosomal enzymes and radioactive calcium from fetal bone in organ culture","volume":"103","author":"G Eilon","year":"1978","journal-title":"Endocrinology"},{"key":"87","doi-asserted-by":"crossref","first-page":"12517","DOI":"10.1074\/jbc.271.21.12517","article-title":"Proteolytic activity of human osteoclast cathepsin K-expression, purification, activation, and substrate identification","volume":"271","author":"M Bossard","year":"1996","journal-title":"J Biol Chem"},{"key":"88","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1074\/jbc.271.21.12511","article-title":"Cathepsin K, but not cathepsin B, L, or S, is abundantly expressed in human osteoclasts","volume":"271","author":"F Drake","year":"1996","journal-title":"J Biol Chem"},{"key":"89","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","article-title":"Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis","volume":"192","author":"H Min","year":"2000","journal-title":"J Exp Med"},{"key":"90","first-page":"2572","article-title":"Therapeutic efficacy of soluble RANK-IgG Fc (RANK.Fc) fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy","volume":"61","author":"B Oyajobi","year":"2001","journal-title":"Cancer Res"},{"key":"91","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1172\/JCI116032","article-title":"Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice","volume":"90","author":"B Boyce","year":"1992","journal-title":"J Clin Invest"},{"key":"92","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1073\/pnas.90.10.4485","article-title":"Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts","volume":"90","author":"C Lowe","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"93","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/nm1197-1189","article-title":"NFkappaB and bone: the breaking point","volume":"3","author":"Y Abu-Amer","year":"1997","journal-title":"Nat Med"},{"key":"94","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation <i>in vivo<\/i> and <i>in vitro<\/i>","volume":"111","author":"I Garrett","year":"2003","journal-title":"J Clin Invest"},{"key":"95","first-page":"683","article-title":"Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women","volume":"77","author":"F Tremollieres","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"96","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0092-8674(00)81558-5","article-title":"Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass","volume":"100","author":"P Ducy","year":"2000","journal-title":"Cell"},{"key":"97","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jbmr.5650080507","article-title":"Effects of weight and body mass indeks on bone mineral density in men and women: the Framingham Study","volume":"8","author":"D Felson","year":"1993","journal-title":"J Bone Miner Res"},{"key":"98","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","article-title":"Osteoclast-derived activity in the coupling of bone formation to resorption","volume":"11","author":"T Martin","year":"2005","journal-title":"Trends Mol Med"}],"container-title":["Archives of Industrial Hygiene and Toxicology"],"original-title":[],"link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/aiht\/58\/1\/article-p55.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/view\/j\/aiht.2007.58.issue-1\/v10004-007-0009-3\/v10004-007-0009-3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T16:02:45Z","timestamp":1707753765000},"score":1,"resource":{"primary":{"URL":"https:\/\/content.sciendo.com\/doi\/10.2478\/v10004-007-0009-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":98,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.2478\/v10004-007-0009-3","relation":{},"ISSN":["0004-1254"],"issn-type":[{"value":"0004-1254","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3,1]]}}}